Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.
Brain Res · 2010
Last updated 2026-05-28In rats, the GLP-1 drug exenatide reduced sugar intake when given in doses of 0.1, 0.5, 5, or 10 micrograms per kilogram. The drug also activated nerve cells in the stomach and brain areas that control eating, and blocking the GLP-1 receptor reversed these effects.
AI summary of the abstract below.
| Journal | Brain Res, 2010 |
|---|---|
| Citations | 50 |
| Relative citation ratio | 1.41 |
| NIH percentile | 62 |
| Molecules | exenatide |
| Conditions studied | Obesity |
Abstract
UNLABELLED: Exenatide is a synthetic agonist of the glucagon-like peptide-1 (GLP-1) receptor, which has also been shown to reduce food intake. The goal of this work is to test the hypothesis that exenatide reduces food intake and activates the enteric nervous system (ENS; myenteric and submucosal plexuses) of the gastrointestinal (GI) tract and the areas of the dorsal vagal complex (DVC) of the hindbrain that control food intake. EXPERIMENT 1: Five groups of overnight food-deprived male Sprague Dawley rats were injected with exenatide (0.1, 0.5, 5 and 10 microg/kg) or saline intraperitoneally, and the intake of 10% sucrose solution was measured at 5 min intervals for 120 min. All doses of exenatide reduced sucrose intake following the 20 min time point, and pretreatment with exendin (9-39), a GLP-1 receptor antagonist, reversed this reduction. EXPERIMENTS 2 AND 3: Following overnight food deprivation, five groups of rats were injected with the treatments listed above and sacrificed 90 min following the injections. The myenteric and submucosal plexuses and DVC were processed for detection of Fos-like immunoreactivity (Fos-LI; a marker for neuronal activation). Exenatide increased Fos-LI dose-dependently in the myenteric and submucosal neurons of the duodenum, but not jejunum and ileum, and in the areas of the DVC that regulate food intake e.g. area postrema, nucleus tractus solitaries and dorsal motor nucleus of the vagus. In addition, pretreatment with exendin (9-39) prior to exenatide injection blocked the activation in both locations.
CONCLUSIONS: Activation of the enteric neurons by exenatide may be part of the pathway by which this peptide reduces food intake.
Verbatim abstract via PubMed 20452329 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.